When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor

Science Signaling

Volumn 2, Issue 61, 2009, Pages

  Su, Tsung Ping ^a   Hayashi, Teruo ^a   Vaupel, D Bruce ^b  

^a Cellular Neurobiology Research Branch   (United States)

^b Intramural Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHAPERONE; IMMUNOGLOBULIN; ION CHANNEL; N,N DIMETHYLTRYPTAMINE; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; SIGMA 1 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

BRAIN; CALCIUM SIGNALING; CELL MEMBRANE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOPLASMIC RETICULUM; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; HUMAN; METABOLISM; PHYSIOLOGY;

BRAIN; HALLUCINOGENS; HUMANS; MODELS, BIOLOGICAL; N,N-DIMETHYLTRYPTAMINE; RECEPTORS, SIGMA; SIGNAL TRANSDUCTION;

EID: 66149131076     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.261pe12     Document Type: Review

References (45)

1. R. T. Premont, R. R. Gainetdinov, M. G. Caron, Following the trace of elusive amines. Proc. Natl. Acad. Sci. U.S.A. 98, 9474-9475 (2001).
2. D. J. McKenna, G. H. Towers, F. Abbott, Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-car-boline constituents of ayahuasca. J. Ethnopharmacol. 10, 195-223 (1984). (Pubitemid 14081500)
3. C. Gambelunghe, K. Aroni, R. Rossi, L. Moretti, M. Bacci, Identification of N,N-dimethyltryptaime and beta-carbolines in psychotropic ayahuasca beverage. Biomed. Chromatogr. 22, 1056-1059 (2008).
4. I. Szara, A. Sai-Halasz, Z. Boszormenyi, Dimethyltryptamine as a new psychotic agent. Acta Physiol. Hung. 11, 78-79 (1957).
5. A. Sai-Halasz, G. Brunecker, S. Szara, Dimethyl-tryptamine: A new psychoactive drug. Psychiatr. Neurol. (Basel) 135, 285-301 (1958).
6. J. M. Saavedra, J. Axelrod, Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science 175, 1365-1366 (1972).
7. R. J. Strassman, C. R. Qualls, Dose-dependent study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch. Gen. Psychiatry 51, 85-97 (1994).
8. R. J. Strassman, C. R. Qualls, E. H. Uhlenhuth, R. Kellner, Dose-response study of N,N-dimethyl-tryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch. Gen. Psychiatry 51, 98-108 (1994).
9. J. Riba, A. Rodrihuez-Fornells, G. Urbano, A. Morte, R. Antonijoan, M. Montero, J. C. Callaway, M. J. Barbanoj, Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berlin) 154, 85-95 (2001).
10. J. Riba, M. Valle, G. Urbano, M. Yritia, A. Morte, M. J. Barbanoj, Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite secretion, and pharmacokinetics. J. Pharmacol. Exp. Ther. 306, 73-83 (2003).
11. E. Gouzoulis-Mayfrank, K. Heekeren, A. Neukirch, M. Stoll, C. Stock, M. Obradovic, K. A. Kovar, Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38, 301-311 (2005).
12. K. Heekeren, A. Neukirch, J. Daumann, M. Stoll, M. Obradovic, K. A. Kovar, M. A. Geyer, E. Gouzoulis-Mayfrank, Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J. Psychopharmacol. 21, 312-320 (2007).
13. K. Heekeren, J. Daumann, A. Neukirch, C. Stock, W. Kawohl, C. Norra, T. D. Waberski, E. Gouzoulis-Mayfrank, Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berlin) 199, 77-88 (2008).
14. J. Daumann, K. Heekeren, A. Neukirch, C. M. Thiel, W. Moller-Hartmann, E. Gouzoulis-Mayfrank, Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berlin) 200, 573-583 (2008).
15. J. P. Bennett Jr., S. H. Snyder, Serotonin and lysergic acid diethylamide binding in rat brain membranes: Relationship to post-synaptic serotonin receptors. Mol. Pharmacol. 12, 373-389 (1976).
16. P. Jenner, C. D. Marsden, C. M. Thanki, Behavioural changes induced by N,N-dimethyl-tryptamine in rodents. Br. J. Pharmacol. 63, 380P (1978).
17. A. V. Deliganis, P. A. Pierce, S. J. Peroutka, Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors. Biochem. Pharmacol. 41, 1739-1744 (1991).
18. B. Borowsky, N. Adham, K. A. Jones, R. Raddatz, R. Artymyshyn, K. L. Ogozalek, M. M. Durkin, P. P. Lakhlani, J. A. Bonini, S. Pathirana, T. A. Boyle, X. Pu, E. Kouranova, H. Lichtblau, F. Y. Ochoa, T. A. Branchek, C. Gerald, Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 98, 8966-8971 (2001).
19. J. R. Bunzow, M. S. Sonders, S. Arttamangkul, L. M. Harrison, G. Zhang, D. I. Quigley, T. Darland, K. L. Suchland, S. Pasumamula, J. L. Kennedy, S. B. Olson, R. E. Magenis, S. G. Amara, D. K. Grandy, Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the cate-cholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 60, 1181-1188 (2001).
20. T. D. Wolinsky, C. J. Swanson, K. E. Smith, H. Zhong, B. Borowsky, P. Seeman, T. Branchek, C. P. Gerald, The trace amine 1 receptor knockout mice: An animal model with relevance to schizophrenia. Genes Brain Behav. 6, 628-639 (2007).
21. J. Duan, M. Martinez, A. R. Sanders, C. Hou, N. Saitou, T. Kitano, B. J. Mowry, R. R. Crowe, J. M. Silverman, D. F. Levinson, P. V. Gejman, Polymorphisms in the trace amine receptor 4 (TAAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia. Am. J. Hum. Genet. 75, 624-638 (2004).
22. D. Amann, N. Avidan, K. Kanyas, Y. Kohn, A. Hamdan, E. Ben-Asher, F. Macciardi, J. S. Beckmann, D. Lancet, B. Lerer, The trace amine receptor 4 gene is not associated with schizophrenia in a sample linked to chromosome 6q23. Mol. Psychiatry 11, 119-121 (2006).
23. V. I. Vladimirov, B. S. Maher, B. Wormley, F. A. O'Neill, D. Walsh, K. S. Kendler, B. P. Riley, The trace amine associated receptor (TAAR6) gene is not associated with schizophrenia in the Irish case-control study of schizophrenia (ICCSS) sample. Schizophr. Res. 107, 249-254 (2009).
24. D. Fontanilla, M. Johannessen, A. R. Hajipour, N. V. Cozzi, M. B. Jackson, A. E. Ruoho, The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323, 934-937 (2009).
25. Z. X. Cheng, D. M. Lan, P. Y. Wu, Y. H. Zhu, Y. Dong, L. Ma, P. Zheng, Neurosteroid dehy-droepiandrosterone sulfate inhibits persistent sodium current in rat medial prefrontal cortex via activation of sigma-1 receptors. Exp. Neurol. 210, 128-136 (2008).
26. F. Langa, X. Condony, V. Tovar, A. Lavado, E. Gimenez, P. Cozar, M. Cantero, A. Dordal, E. Hernandez, R. Perez, X. Monroy, D. Zamanillo, X. Guitart, L. Montoliu, Generation and phenotypic analysis of sigma receptor type 1 (sigma 1) knockout mice. Eur. J. Neurosci. 18, 2188-2196 (2003).
27. W. R. Martin, C. G. Eades, J. A. Thompson, R. E. Huppler, P. E. Gilbert, The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532 (1976).
28. D. B. Vaupel, Naltrexone fails to antagonize the sigma effects of PCP and SKF-10047 in the dog. Eur. J. Pharmacol. 92, 269-274 (1983).
29. 3H]SKF-10047 to etorphine-inaccessible site in guinea pig brain. J. Pharmacol. Exp. Ther. 223, 284-290 (1982).
30. T.-P. Su, E. D. London, J. H. Jaffe, Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 240, 219-221 (1988).
31. S. B. Hellewell, A. Bruce, G. Feinstein, J. Orringer, W. Williams, W. D. Bowen, Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: Characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 268, 9-18 (1994).
32. S. H. Snyder, B. L. Largent, Receptor mechanisms in antipsychotic drug action: Focus on sigma receptors. J. Neuropsychiatry Clin. Neurosci. 1, 7-15 (1989).
33. T. L. Collier, R. N. Waterhouse, M. Kassiou, Imaging sigma receptors: Applications in drug development. Curr. Pharm. Des. 13, 51-72 (2007). (Pubitemid 46085300)
34. T. Hayashi, T.-P. Su, Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 131, 596-610 (2007).
35. T. Hayashi, R. Rizzuto, G. Hajnoczky, T.-P. Su, Trends Cell Biol. 19, 81 (2009).
36. T. Hayashi, T.-P. Su, Intracellular dynamics of sigma-1 receptors in NG-108-15 cells. J. Pharmacol. Exp. Ther. 306, 726-733 (2003).
37. T. A. Mavlyutov, A. Ruoho, Ligand-dependent localization and intracellular stability of sigma-1 receptors in CHO-K1 cells. J. Mol. Signal. 2, 8 (2007).
38. E. Aydar, C. P. Palmer, V. A. Klyachko, M. B. Jackson, The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34, 399-410 (2002).
39. M. Martina, M. E. Turcotte, S. Halman, R. Begeron, The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J. Physiol. 578, 143-157 (2007).
40. H. Zhang, J. Cuevas, Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. J. Neurophysiol. 87, 2867-2879 (2002).
41. Y. Herrera, C. Katnik, J. D. Rodriguez, A. A. Hall, A. Willing, K. R. Pennypacker, J. Cuevas, Sigma-1 receptor modulation of acid-sensing ion channel a (ASICa) and ASICa-induced Ca2+ influx in rat cortical neurons. J. Pharmacol. Exp. Ther. 327, 491-502 (2008).
42. A. Renaudo, S. L'Hoste, H. Guizouarn, F. Borgese, O. Soriani, Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. J. Biol. Chem. 282, 2259-2267 (2007).
43. A. Urani, P. Romieu, F. J. Roman, T. Maurice, Enhanced antidepressant effect of sigma-1 receptor agonists in β25-35-amyloid peptide-treated mice. Behav. Brain Res. 134, 239-247 (2002).
44. J. Axelrod, Enzymatic formation of psychotomimetic metabolites from normally occurring compounds. Science 134, 343 (1961).
45. This work was supported by the Intramural Research Program of the National Institute on Drug Abuse, NIH, Department of Health and Human Services of the United States.